K
Kathryn Hobbs
Researcher at University of Colorado Denver
Publications - 19
Citations - 14759
Kathryn Hobbs is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Epratuzumab & Placebo. The author has an hindex of 15, co-authored 19 publications receiving 12421 citations. Previous affiliations of Kathryn Hobbs include University of California, Los Angeles & University of Colorado Hospital.
Papers
More filters
Journal ArticleDOI
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Daniel Aletaha,Tuhina Neogi,Alan J. Silman,Julia Funovits,David T. Felson,Clifton O. Bingham,Neal S. Birnbaum,Gerd Burmester,Vivian P. Bykerk,Marc D. Cohen,Bernard Combe,Karen H. Costenbader,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,Johanna M. W. Hazes,Kathryn Hobbs,Tom W J Huizinga,Arthur Kavanaugh,Jonathan Kay,Tore K Kvien,Timothy J. Laing,Philip J. Mease,Henri A Ménard,Larry W. Moreland,Raymond L. Naden,Theodore Pincus,Josef S Smolen,Ewa Stanislawska-Biernat,Deborah P M Symmons,Paul P. Tak,Katherine S. Upchurch,Jiří Vencovský,Frederick Wolfe,Gillian A. Hawker +34 more
TL;DR: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features.
Journal ArticleDOI
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Daniel Aletaha,Tuhina Neogi,Alan J. Silman,Julia Funovits,David T. Felson,Clifton O. Bingham,Neal S. Birnbaum,Gerd Burmester,Vivian P. Bykerk,Marc D. Cohen,Bernard Combe,Karen H. Costenbader,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,Johanna M. W. Hazes,Kathryn Hobbs,Tom W J Huizinga,Arthur Kavanaugh,Jonathan Kay,Tore K Kvien,Timothy J. Laing,Philip J. Mease,Henri A Ménard,Larry W. Moreland,Raymond L. Naden,Theodore Pincus,Josef S Smolen,Ewa Stanislawska-Biernat,Deborah P M Symmons,Paul P. Tak,Katherine S. Upchurch,Jiří Vencovský,Frederick Wolfe,Gillian A. Hawker +34 more
TL;DR: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features.
Journal ArticleDOI
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report
Tuhina Neogi,Daniel Aletaha,Alan J. Silman,Raymond L. Naden,David T. Felson,Rohit Aggarwal,Clifton O. Bingham,Neal S. Birnbaum,Gerd R Burmester,Vivian P. Bykerk,Marc D. Cohen,Bernard Combe,Karen H. Costenbader,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,Johanna M. W. Hazes,Kathryn Hobbs,Tom W J Huizinga,Arthur Kavanaugh,Jonathan Kay,Dinesh Khanna,Tore K Kvien,Timothy J. Laing,Katherine P. Liao,Philip J. Mease,Henri A. Ménard,Larry W. Moreland,Raj Nair,Theodore Pincus,Sarah Ringold,Josef S Smolen,Ewa Stanislawska-Biernat,Deborah P M Symmons,Paul P. Tak,Katherine S. Upchurch,Jiří Vencovský,Frederick Wolfe,Gillian A. Hawker +38 more
TL;DR: The expert panel agreed that the new classification criteria should be applied to individuals with undifferentiated inflammatory arthritis in whom at least 1 joint is deemed by an expert assessor to be swollen, indicating definite synovitis.
Journal ArticleDOI
Interleukin-10 and transforming growth factor-β promoter polymorphisms in allergies and asthma
TL;DR: This work investigated the hypothesis that polymorphic nucleotides within the IL-10 and TGF-beta gene promoters would link to the expression of allergies and asthma and demonstrated the presence of a polymorphism in the promoter region of theIL-10 gene.
Journal ArticleDOI
The benefit/risk profile of TNF-blocking agents : Findings of a consensus panel
TL;DR: TNF-blockers are effective and may be safely used for short- and long-term management of RA or CD and also show efficacy in other emerging indications.